Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion

Oncogene volume 21, pages 1217–1224 (2002)Cite this article

Abstract

Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was first identified as a positive mediator of programmed cell death. Loss of DAP kinase expression was first demonstrated in highly metastatic cells, whilst re-expression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been defined. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT–PCR analysis. Loss of DAP kinase expression was significantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their non-invasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, five (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was significantly (P=<0.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or five histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the first report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Bates AS, Farrell WE, Bicknell EJ, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN . 1997 J. Clin. Endo. Metab. 82: 818–824

  • Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-P . 1998 Adv. Cancer Res. 72: 141–196

  • Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, Mcternan P, Perrett CW, Thakker RV, Clayton RN . 1994 J. Clin. Endo. Metab. 78: 387–392

  • Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • Cohen O, Feinstein E, Kimichi A . 1997 EMBO J. 16: 998–1008

  • Costello JF, Berger MS, Su Huang H-J, Cavenee WK . 1996 Cancer Res. 56: 2405–2410

  • Deiss LP, Feinstein E, Berissi H, Cohen O, Kimichi A . 1995 Genes Dev. 9: 15–30

  • Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG . 1999 Cancer Res. 59: 67–70

  • Evan G, Littlewood T . 1998 Science 281: 1317–1322

  • Farrell WE, Simpson DJ, Bicknell EJ, Talbot AJ, Bates AS, Clayton RN . 1997 Cancer Res. 57: 2703–2709

  • Feinstein E, Druck T, Kastury K, Berissi H, Goodart SA, Overhauser J, Kimichi A, Huebner K . 1995a Genomics 29: 305–307

  • Feinstein E, Kimichi A . 1995b TIBS 342–344

  • Grigg GW . 1996 DNA Seq. 6: 189–198

  • Hardy J . 1979 Recent advances in the treatment and diagnosis of pituitary tumours New York: Raven pp 375–388

    Google Scholar 

  • Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadal E, Elsenbach L, Kimichi A . 1997 Nature 390: 180–184

  • Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nayata S . 1991 Cell 66: 233–243

  • Jones PA . 1996 Cancer Res. 56: 2463–2467

  • Katzenellenbogen RA, Baylin SB, Herman JG . 1999 Blood 93: 4347–4353

  • Kissill JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, Eydmann ME, Kimichi A . 1997 Oncogene 15: 403–407

  • Laster SM, Wood JG, Gooding LR . 1998 J. Immunol. 141: 2629–2634

  • Lin JK, Chou CK . 1992 Cancer Res. 52: 385–388

  • Martin SJ, Green DR, Cotter TG . 1994 Trends Biochem. Sci. 19: 26–30

  • Nakatsuka S-I, Takakuwa T, Tomita Y, Miwa H, Matsuzuka F, Aozasa K . 2000 Lab. Invest. 80: 1651–1655

  • Novelli F, Di Pierro F, Di Celle PF, Bertini S, Affaticati P, Garotta G, Forni G . 1994 J. Immunol. 152: 496–504

  • Raff MC . 1992 Nature 356: 397–400

  • Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimichi A . 2001 Nat. Cell. Biol. 3: 1–7

  • Sanchez-Cespedes M, Esteller M, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D . 2000 Cancer Res. 60: 892–895

  • Schwartz LM, Osborne BA . 1993 Immunol. Today 14: 582–590

  • Simpson DJ, Bicknell EJ, McNicol AM, Clayton RN, Farrell WE . 1999a Genes, Chromosomes Cancer 24: 328–336

  • Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, Farrell WE . 2001 Carcinogenesis 22: 101–106

  • Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE . 2000 Cancer Res. 60: 1211–1216

  • Simpson DJ, Magnay J, Bicknell EJ, Barkan AL, McNicol AM, Clayton RN, Farrell WE . 1999b Cancer Res. 59: 1562–1566

  • Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L . 2000 J. Natl. Cancer Inst. 92: 1511–1516

  • Ueki T, Toyota M, Sohn T, Yeo CJ, Issa J-P J, Hruban RH, Goggins M . 2000 Cancer Res. 60: 1835–1839

  • Wyllie AH, Kerr JF, Currie AR . 1980 Int. Rev. Cytol. 68: 251–306

  • Zingg JM, Jones PA . 1997 Carcinogenesis 18: 869–882

Download references

Acknowledgements

We would like to thank Dr M Pfiefer for clinical material and Prof G Williams for valuable scientific contribution during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke-on-Trent, ST4 7QB, UK

    D J Simpson, R N Clayton & W E Farrell

Authors
  1. D J Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R N Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W E Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W E Farrell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, D., Clayton, R. & Farrell, W. Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21, 1217–1224 (2002). https://doi.org/10.1038/sj.onc.1205195

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205195

Keywords

This article is cited by

Search

Advanced search

Quick links